Ligand Pharmaceuticals
LGND • NASDAQ
Ligand Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Todd C. Davis, with a market cap of $3.9B.
CEOTodd C. Davis
Next Earnings
Upcoming earnings announcement for Ligand Pharmaceuticals
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.51
Revenue Estimate
$59.4M
Earnings History
Past 12 earnings reports for Ligand Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $2.02Est: $1.15 | +75.7% | $59.7MEst: $56.6M | +5.4% |  10-K |
| Nov 6, 2025 | Q3 2025 | $3.09Est: $1.57 | +96.8% | $115.5MEst: $58.5M | +97.2% | 10-Q |
| Aug 7, 2025 | Q2 2025 | $1.60Est: $0.94 | +70.2% | $47.6MEst: $44.6M | +6.8% | 10-Q |
| May 8, 2025 | Q1 2025 | $1.33Est: $1.21 | +9.9% | $45.3MEst: $37.8M | +19.8% | 10-Q |
| Feb 27, 2025 | Q4 2024 | $1.27Est: $1.19 | +6.7% | $42.8MEst: $39.0M | +9.7% | 10-K |
| Nov 7, 2024 | Q3 2024 | $1.84Est: $1.35 | +36.3% | $51.8MEst: $40.7M | +27.5% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $1.40Est: $0.98 | +42.9% | $41.5MEst: $31.9M | +30.2% | 10-Q |
| May 7, 2024 | Q1 2024 | $3.84Est: $0.78 | +392.3% | $31.0MEst: $27.9M | +11.0% | 10-Q |
| Feb 27, 2024 | Q4 2023 | $1.38Est: $0.66 | +109.1% | $28.1MEst: $25.7M | +9.3% | 10-K |
| Nov 8, 2023 | Q3 2023 | $1.02Est: $0.61 | +67.2% | $32.9MEst: $27.2M | +20.9% | — |
| Aug 8, 2023 | Q2 2023 | $1.42Est: $0.64 | +121.9% | $26.4MEst: $25.7M | +2.5% | 10-Q |
| May 4, 2023 | Q1 2023 | $2.28Est: $0.89 | +156.2% | $44.0MEst: $34.0M | +29.2% | — |